Back to Journals » OncoTargets and Therapy » Volume 11

Elemene treatment for NSCLC with multiple CNS metastases: a case report and literature review

Authors Han YS, Zhang X, Lu Y, Dong Y, Fu H, Zhang B, Gao Y

Received 28 December 2017

Accepted for publication 14 July 2018

Published 2 October 2018 Volume 2018:11 Pages 6377—6382

DOI https://doi.org/10.2147/OTT.S160970

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 5

Editor who approved publication: Professor Jianmin Xu


Yushan Han,1,* Xia Zhang,2,* Yishan Lu,3,4 Yan Dong,1 Hong Fu,1 Bin Zhang,1 Yajie Gao1

1Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, People’s Republic of China; 2Department of Oncology, The Fifth People’s Hospital of Dalian, Dalian, People’s Republic of China; 3Queen Mary University of London, London, UK; 4Nanchang University, Nanchang, People’s Republic of China

*These authors contributed equally to this work

Abstract: CNS metastases are common in patients with non-small-cell lung cancer (NSCLC) and is associated with poor prognosis. In NSCLC patients with EGFR mutations, and ALK fusion oncogene, chemotherapy is ineffective; however, targeted and pulse therapies may be used as alternative treatment options. Elemene can cross the blood–brain barrier and enter the brain tissue. In this paper, treatment consisting of elemene injections in a case of NSCLC with brain metastases, spinal metastases and a possible complication of leptomeningeal metastases is reported, and the efficacy of elemene in treating NSCLC with CNS metastases was investigated.

Keywords: NSCLC, CNS metastases, elemene

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]